AIQ Solutions

4:00 PM - 4:15 PM (PDT), Wednesday, June 15, 2022
AIQ Solutions has developed imaging biomarkers to better evaluate and predict treatment response for complex diseases, starting with late-stage cancers. Oncologists use AIQ’s products to improve patient outcomes through better therapy optimization; pharmaceutical companies use them in Phase I and II trials to improve go/no-go decisions on drug candidates. The analysis is executed in the cloud and sold using a SaaS business model. AIQ has business operations in the US and Australia. The company raised a Series A in late 2021 and plans a Series B growth round in late 2023.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
TRAQinform IQ software
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided